Cyrano plans to enrol 150 patients in the study. Credit: Kmpzzz / Shutterstock.com.

Cyrano Therapeutics has started enrolment in the Phase II FLAVOR trial of CYR-064, a new soft-mist nasal spray product candidate, for post-viral smell loss (hyposmia).

The placebo-controlled, multi-dose study will evaluate the local nasal safety, effectiveness and tolerability of CYR-064 against placebo in post-viral hyposmia treatment for six months.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Cyrano plans to enrol around 150 patients in the randomised and double-blinded study.

The multi-institutional prospective trial is being carried out at 15 US clinical sites.

Cyrano Therapeutics president and CEO Rick Geoffrion said: “We are excited to announce a significant milestone in our commitment to advancing medical science and improving the lives of those affected by post-viral smell loss.

See Also:

    “With the enrolment of the first patients in our Phase II trial of CYR-064, we take a giant step forward in addressing a pressing health concern.

    How well do you really know your competitors?

    Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

    Company Profile – free sample

    Thank you!

    Your download email will arrive shortly

    Not ready to buy yet? Download a free sample

    We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

    By GlobalData
    Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

    “In a world where post-viral smell loss continues to affect an ever-growing number of individuals, we’re dedicated to pioneering solutions that make a difference.”

    Post-viral hyposmia is a growing and serious chronic sensory condition, with no approved drug treatment available at present.

    Hyposmia in older individuals is linked to increased cognitive impairment and mortality risk.

    Before the Covid-19 pandemic, approximately eight million people in Europe and the US experienced long-term post-viral hyposmia.

    This pandemic has led to a significant rise in the number of people experiencing long-term post-viral hyposmia.